JPMorgan Chase & Co. Sells 37,348 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

JPMorgan Chase & Co. trimmed its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 0.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,087,506 shares of the company’s stock after selling 37,348 shares during the period. JPMorgan Chase & Co. owned 1.95% of Allogene Therapeutics worth $11,445,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Federated Hermes Inc. purchased a new position in shares of Allogene Therapeutics during the 2nd quarter valued at $29,000. Private Advisor Group LLC purchased a new stake in shares of Allogene Therapeutics during the 3rd quarter valued at $34,000. Algert Global LLC purchased a new stake in shares of Allogene Therapeutics during the 2nd quarter valued at $35,000. MML Investors Services LLC bought a new position in Allogene Therapeutics in the third quarter valued at $56,000. Finally, AQR Capital Management LLC purchased a new stake in Allogene Therapeutics during the second quarter valued at about $64,000. Institutional investors own 83.63% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a research report on Friday, November 8th. William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Finally, Piper Sandler decreased their target price on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.73.

Allogene Therapeutics Price Performance

NASDAQ:ALLO opened at $2.06 on Monday. The firm has a market capitalization of $431.92 million, a price-to-earnings ratio of -1.32 and a beta of 0.86. The business has a fifty day moving average price of $2.32 and a 200-day moving average price of $2.54. Allogene Therapeutics, Inc. has a one year low of $1.78 and a one year high of $5.78.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).